Kymera Therapeutics is a biotechnology company focused on developing innovative therapies for autoimmune diseases and cancer. Its core products include targeted protein degradation therapies, which aim to selectively eliminate disease-causing proteins. The company operates primarily in the healthcare sector, with major revenue sources stemming from research collaborations and potential future product sales.
The investment profile of Kymera Therapeutics is more aligned with growth investors due to its focus on innovative therapies and significant revenue growth potential. The absence of dividends and the company's current financial metrics suggest a higher risk profile, making it suitable for those with a longer investment horizon who can tolerate volatility.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-09-23 | Hold | Buy | Strong revenue growth and positive EPS surprise signal potential. |
| 2026-09-10 | Buy | Hold | Strong revenue growth, but negative EPS and high risk. |
| 2026-09-02 | Hold | Buy | Strong revenue growth, but negative EPS raises concerns. |
| 2026-08-26 | Buy | Hold | Strong revenue growth, but negative EPS raises concerns. |
| 2026-08-18 | Hold | Buy | Strong revenue growth and positive momentum indicators. |
| 2026-08-11 | Sell | Hold | Strong revenue growth, but negative EPS and high risk. |
| 2026-08-04 | Hold | Sell | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-07-27 | Buy | Hold | High volatility with uncertain fundamentals and mixed momentum. |
| 2026-07-19 | Hold | Buy | Strong revenue growth, but negative EPS raises concerns. |
| 2026-07-11 | Buy | Hold | Strong momentum, but high EPS loss raises concerns. |
| 2026-07-03 | Hold | Buy | Strong revenue growth, but negative EPS raises concerns. |
| 2026-06-26 | — | Hold | Strong momentum but negative EPS indicates caution. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-09-22 | Stifel Nicolaus | Target Raised | 132 → 152 | 117.67 |
| 2026-09-10 | Wolfe Research | Rating Upgraded | — → 180 | 115.43 |
| 2026-08-31 | Guggenheim | Target Raised | — → 170 | 118.15 |
| 2026-08-06 | Morgan Stanley | Target Raised | 119 → 135 | 104.9566 |
| 2026-08-06 | Barclays | Target Raised | 133 → 139 | 105.48 |
| 2026-08-05 | Oppenheimer | Target Raised | — → 125 | 105.48 |
| 2026-07-30 | Deutsche Bank | Update | — → 120 | 105.25 |
| 2026-07-28 | Guggenheim | Target Raised | 125 → 135 | 110.05 |
| 2026-07-16 | Mizuho Securities | Target Raised | 120 → 140 | 114.12 |
| 2026-07-13 | RBC Capital | Rating Downgraded | — → 115 | 119.35 |
| 2026-06-29 | Truist Financial | Target Raised | 116 → 136 | 108.12 |
| 2026-06-26 | Canaccord Genuity | Target Raised | 106 → 129 | 116.46 |
| 2026-06-26 | B.Riley Financial | Target Raised | — → 155 | 116.46 |
| 2026-06-08 | Loop Capital Markets | Target Raised | — → 97 | 73.95 |
| 2026-05-06 | Canaccord Genuity | Update | — → 106 | 82.71 |
| 2026-04-30 | Morgan Stanley | Target Lowered | 123 → 119 | 80.73 |
| 2026-02-26 | Morgan Stanley | Target Lowered | — → 123 | 95.03 |
| 2026-02-26 | RBC Capital | Target Raised | — → 108 | 91.8657 |
| 2026-01-27 | Barclays | Update | — → 133 | 72.15 |
| 2025-12-16 | RBC Capital | Target Raised | 70 → 103 | 85.62 |
| 2025-12-11 | Stephens | Target Raised | 65 → 110 | 89.895 |
| 2025-12-11 | Mizuho Securities | Target Raised | 81 → 120 | 89.895 |
| 2025-12-09 | Jefferies | Target Raised | 73 → 122 | 86.82 |
